Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2016, specifically dated September 13, 2016. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change reported is the receipt of a Notice of Allowance from the European Patent Office (EPO) regarding a patent titled "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-MECA/CF-101) for Treatment of Psoriasis."
Outlook, Risks, and Management Commentary
Management announced the patent allowance via a press release attached as Exhibit 99.1. The filing does not provide specific financial guidance, discuss general risks, or detail contingencies beyond the patent status update.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the patent scope and jurisdiction.
- Confirm the status of the IB-MECA/CF-101 clinical development program for psoriasis.
- Review subsequent filings for any updates on the patent grant or related regulatory milestones.